Search Within

Ariela Noy

Formats
  1. Meeting Abstract (204)
  2. Journal Article (143)
  3. Research Letter (10)
  4. Book Section (6)
  5. Review (6)
  6. Editorial (2)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (373)
  2. Department of Medicine (373)
  3. Hematologic Malignancies, Division of (373)
  4. Lymphoma (373)
  5. Survivorship Research (163)
  6. Population Sciences Research Program (150)

More Groups

People
  1. Andrew Zelenetz (187)
  2. Paul Hamlin (144)
  3. David Straus (139)
  4. Steven Horwitz (138)
  5. Maria Palomba (131)
  6. Alison Moskowitz (118)

More People

Years
  1. 2025 (9)
  2. 2024 (27)
  3. 2023 (24)
  4. 2022 (15)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (166)
  2. Journal of Clinical Oncology (42)
  3. Hematological Oncology (19)
  4. Leukemia and Lymphoma (15)
  5. Blood Advances (13)
  6. Annals of Oncology (12)

More Publications

Publishers
  1. American Society of Hematology (179)
  2. American Society of Clinical Oncology (43)
  3. Wiley Blackwell (23)
  4. Elsevier Inc. (21)
  5. Taylor & Francis Group (15)
  6. Ferrata Storti Foundation (12)

More Publishers

Results (373)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes in mantle cell lymphoma with central nervous system involvement - A dual center study
    Meeting Abstract

    McLaughlin, N.; Joseph, A.; Wang, Y. C.; Pederson, L. D.; Geyer, S. M.; Witzig, T. E.; Zelenetz, A. D.; Villasboas, J. C. C.; Scordo, M.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
    Journal Article

    Laracy, J. C.; Yan, J.; Steiger, S. N.; Tan, C. A.; Cohen, N.; Robilotti, E. V.; Fender, J.; Cohen, S.; Korde, N.; Lee-Teh, M.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry
    Research Letter

    Luttwak, E.; Noy, A.; Seshan, V.; Saltzman, L. A.; Greenberger, L. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
    Research Letter

    Lakhotia, R.; Dunleavy, K.; Abramson, J. S.; Link, B. K.; Powell, B. L.; Melani, C.; Lucas, A. N.; Steinberg, S. M.; Friedberg, J. W.; Kahl, B. S.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save